Raymond James Financial Inc. Makes New Investment in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Raymond James Financial Inc. purchased a new stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 727,118 shares of the biotechnology company’s stock, valued at approximately $3,628,000.

Several other institutional investors have also recently made changes to their positions in the business. Geode Capital Management LLC increased its stake in shares of Aldeyra Therapeutics by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 1,119,555 shares of the biotechnology company’s stock worth $5,588,000 after purchasing an additional 4,927 shares in the last quarter. State Street Corp grew its holdings in Aldeyra Therapeutics by 1.7% during the third quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock valued at $5,249,000 after purchasing an additional 16,188 shares during the period. ADAR1 Capital Management LLC increased its position in Aldeyra Therapeutics by 114.4% in the fourth quarter. ADAR1 Capital Management LLC now owns 647,960 shares of the biotechnology company’s stock worth $3,233,000 after buying an additional 345,748 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Aldeyra Therapeutics by 1.9% in the fourth quarter. Wells Fargo & Company MN now owns 393,654 shares of the biotechnology company’s stock worth $1,964,000 after buying an additional 7,348 shares during the period. Finally, Woodstock Corp lifted its position in shares of Aldeyra Therapeutics by 7.8% during the 4th quarter. Woodstock Corp now owns 194,919 shares of the biotechnology company’s stock valued at $973,000 after buying an additional 14,113 shares in the last quarter. Institutional investors own 59.71% of the company’s stock.

Insider Buying and Selling at Aldeyra Therapeutics

In other news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the business’s stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the completion of the sale, the insider now directly owns 5,875,851 shares of the company’s stock, valued at approximately $8,343,708.42. The trade was a 36.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 8.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. BTIG Research reduced their price objective on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, April 7th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a report on Friday, April 4th.

Aldeyra Therapeutics Stock Up 0.4 %

NASDAQ ALDX opened at $2.66 on Monday. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18. Aldeyra Therapeutics, Inc has a 52 week low of $1.14 and a 52 week high of $7.20. The firm has a market capitalization of $158.83 million, a price-to-earnings ratio of -2.83 and a beta of 0.94. The company has a fifty day moving average of $4.76 and a two-hundred day moving average of $5.05.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.30). On average, analysts predict that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.